Intended for the physician whose primary discipline is not medical oncology, but whose practice includes women at risk for breast cancer and/or women who are either taking tamoxifen to treat breast cancer, or women who are taking raloxifene to prevent osteoporosis. Also recommended for nurses in breast care centers who are responsible for the day-to-day care of women.

Tamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. It is the first drug targeted therapy in cancer to be successful. Tamoxifen targets the tumor estrogen receptor. The therapy is known to have saved the lives of millions of women over the past 40 years. This monograph, written by V. Craig Jordan - known as the “father of tamoxifen” - and his Tamoxifen Team at the Georgetown University Washington DC, illustrates the journey of this milestone in medicine. It includes a personal interview with V. Craig Jordan about his four decades of discovery in breast cancer research and treatment. V. Craig Jordan was there for the birth of tamoxifen as he is credited for reinventing a “failed morning after contraceptive” to become the “gold standard” for the treatment of breast cancer. He contributed to every aspect of tamoxifen application in therapeutics and all aspects of tamoxifen’s pharmacology. He discovered the selective estrogen receptor modulators (SERMs) and explored the new biology of estrogen-induced apoptosis.

Offering the most comprehensive, up-to-date information on the diagnosis and management of, and rehabilitation following, surgery for benign and malignant diseases of the breast, this surgical reference is now in a new edition available in both print and online for easy, convenient access to the absolute latest advances.

Holland-Frei Cancer Medicine, Ninth Edition, offers a balanced view of the most current knowledge of cancer science and clinical oncology practice. This all-new edition is the consummate reference source for medical oncologists, radiation oncologists, internists, surgical oncologists, and others who treat cancer patients. A translational perspective throughout, integrating cancer biology with cancer management providing an in depth understanding of the disease An emphasis on multidisciplinary, research-driven patient care to improve outcomes and optimal use of all appropriate therapies Cutting-edge coverage of personalized cancer care, including molecular diagnostics and therapeutics Concise, readable, clinically relevant text with algorithms, guidelines and insight into the use of both conventional and novel drugs Includes free access to the Wiley Digital Edition providing search across the book, the full reference list with web links, illustrations and photographs, and post-publication updates

A discussion of the diagnosis of breast cancer and the risks, benefits and limitations of treatment alternatives, particularly tamoxifen. This edition contains information on developments in the use of tamoxifen, especially in the results of the Breast Cancer Prevention Trial.

Tamoxifen was first approved in 1977 and up to now remains a noteworthy therapeutic weapon to treat mainly breast cancer. However, further considerations exist regarding the tamoxifen profile. This book discusses recent research and future perspectives in the tamoxifen field. The topics discussed include tamoxifen pharmacokinetics, pharmacodynamics, adverse effects, clinical indications, therapeutic drug monitoring, autophagy mechanisms, tamoxifen topical formulation and breast cancer risk prevention, the use of tamoxifen in an oestrogen-independent manner for various neoplasms (Hepatocellular carcinoma, renal cell carcinoma, high grade glioma), mechanisms of resistance, potential role of CYP2D6, tamoxifen and antidepressants interaction in a psychiatric view, obesity influence in tamoxifen treatment, electrical pulse-mediated tamoxifen delivery, and tamoxifen in melanoma treatment.